Fig. 6From: Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trialsSimulation of plasma ozoralizumab concentration. Simulated values were compared with the observed values (A) and the concentrations after various dosing intervals were simulated (B)Back to article page